TheDrewster
13 Sep 2015
Still number one [link] 58
aura01
28 Aug 2015
Next year???? There have been a number of posts saying that we will run out of money before the end of the year. This is clearly not going to happen. FS is motoring along nicely and going from strength to strength. The second half of the year is always good for our cash flow vs R&D spend and I expect that we will finish the year with just short of £5m ish.However what I can't guess is what the effect of a lower cash flow in the first half of next year will be, R&D spend H1 2016 vs potential revenue streams from Google / Apple etc vs delays in commercialising Sensium. If Sensium does eventually commercialise, then we are away. I would really like to see us get Bodysense 2 ready for market. This would make a significant difference to early adoption in my view. I also wish that we could have retained Richard Steeves, as he is clearly at the top of his game and a big hitter. I reckon he had a different vision / strategy to our CEO and this was fairly obvious at the AGM.I am still very hopeful for this company for the medium term but don't know whether we will need more money in order to get there. And if we do, it may not necessarily be through equity. I reckon that Richard Steeves is currently off-loading his stock, which is driving the share price down, especially in a market where buyers are on the sidelines hoping to pick up stock in a potential placing.Time will tell and patience is a virtue. I do wish however that we would play to our strengths in presenting the company to the 'outside world'. Anthony Sethill is clearly a strong leader of the business but he is not a 'natural' speaker / salesman for Toumaz.. Patrick Hannon is an excellent presenter with great communication skills and he would be far better at 'selling our story'.....but what do I know?September's trading update should / may give us a bit more of a clue.A
rollthediceagain
25 Aug 2015
Re: Ouch! SP bumps upward that should have read!
rollthediceagain
25 Aug 2015
Re: Ouch! Gritting my teeth holding...I bump upwards as I type 2.25-2.75 (+11%)Markets are going to be a nightmare (probably) for a few weeks yet so I'll hold off bottom fishing and even then it'll be for profitable, debt-light, non-AIM companies!
Mr Google
24 Aug 2015
Re: Ouch! I had a look at the Major shareholders (last updated 19 Aug) on the Toumaz website and it appears the AXA stake remains unchanged since May along with other major shareholders.Don't know who is selling, but I would gather that a lot of the PIs have been selling (at a loss I gather). I have topped with a small amount today, but not advisable for those who feel they are likely to panic.If Toumaz do need funding I would gather they need to do it in the 1H of 2016.My bet is most of the spending for the 1H of 2015 was on the connected audio chip that they will be demonstrating at IFA. The most expensive phase in chip development is usually in manufacturing chips at foundries."Minuet – An integrated, connected audio module engineered from the ground up with support for Google Cast technology for audio devices"[link] do hope the half year results report does make it clear of how much more development needs to be done on Minuet and when the first sales are likely. This will give us a clear indication of whether we face a cash call in 2016.DYOR.
TheDrewster
24 Aug 2015
Re: Ouch! I took some more today. I don't believe they will need more cash, certainly not this year - they will of course need to start delivering some revenue streams to not need any next, but I think its a good price to be adding (famous last words)
may_sell
24 Aug 2015
Re: Ouch! In April I posted that I might be tempted if the price goes below 3p - and I am (but didn't foresee the possibility that it could be below 2p). Suppose the questions are still:a) Will the city stump up for yet another cash call?b) Will Imagination pump in some more cash?As 'rollthediceagain' points out: the trouble is that yes to either or both will dilute the share price still further.(Presumably 'aborman' has been filling his boots with Toumaz stock! 07-04-15: "If you can buy below 4p, i will"
Trek
24 Aug 2015
Re: Ouch! Ouch indeed, can`t see how they can keep operating as one company, got to do something about healthcare side,sell one keep one, which ever, the way it is at the momentbenefits no one.
Mr Google
24 Aug 2015
Re: Ouch! Ouch indeed!Looks like it is oversold due to multiple uncertainties and fears.
rollthediceagain
24 Aug 2015
Re: Ouch! Sp isn't just at 12mths lows, it's at a decade-low!!
rollthediceagain
24 Aug 2015
Ouch! 2.25-2.5p ~ sells outweighing buys for a number of trading periods.Lose H1 £5.5m, cash @ 30thJune also £5.5m @ ~ by year end TMZ will have to pass the hat round which at these rates will destroy shareholder value. If they've reduced cash burn & strong audio sales continue may push need into Q1 I suppose but Sensium now just a money pit with no commercial contracts.TMZ need to make healthcare pay or drop/sell it or it'll pull company down with it.
stratty
10 Aug 2015
Re: RNS v Interview on Proactive The trial at Spire has been successfully completed - and will be used as a basis for further developing the Group's approach to Spire and the broader private hospital sector. A further 19 hospital trials are expected to start shortly. Read into that what you can.
Mr Google
04 Aug 2015
Re: RNS v Interview on Proactive I don't think there is anything wrong with the RNS, it says what it intends to say without the fluff.My view is that they under-estimated how much work there needs to be done when it comes to dealing with hospitals. As I have been saying in the past this will take time and even when the system is proven clinically and economically hospitals will roll it out slowly so that it does not break their existing electronic medical/health record systems. Other things hospitals need to consider is the initial disruption to the ward, training, support, etc. need to be taken into account. The big one is when hospitals do budgeting and that can be 6 months to decide or a year. I don't know if Toumaz have taken these things into account when getting the funding from institutional investors.In the past they did say they needed to carry out a health economic study, and the delay in finding an NHS hospital and getting funding for it might have made the delays longer than needed.The real concern for us is the cash position of the company and further dilution and whether the Frontier Division will make the company profitable by 2H 2016. Whatever funding they may need, needs to take into account the slow pace of progress within Sensium.
Frost41
04 Aug 2015
Re: RNS v Interview on Proactive I can accept that the NHS operates at a snails pace, but I am a little surprised that no deal has been announced with Spire if the business case is so compelling ~ bearing in mind they were one of the first to trial? Does anyone have any idea what happened here?
gronch
04 Aug 2015
Re: RNS v Interview on Proactive "A study conducted at one hospital in America showed that SensiumVitals picked up deterioration in 12% of patients. For these patients, the early warnings provided by SensiumVitals reduced their hospital stay by an average of four days. That works out financially at around US$9,000 per person."So that's a $9k saving for the patient and a $9k loss of revenue for the hospital. Now I understand why it was not taken up after the study :--) Perhaps America wasn't the right place to trial the system. It was too successful for it's own good!!!
